Celularity Inc
NASDAQ:CELU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Redishred Capital Corp (Pre-Merger)
XTSX:KUT
|
CA |
|
A
|
Autoline Industries Ltd
NSE:AUTOIND
|
IN |
|
Brookfield Corp
NYSE:BN
|
CA |
|
Sports Entertainment Group Ltd
ASX:SEG
|
AU |
|
Radian Group Inc
NYSE:RDN
|
US |
|
Mapletree Pan Asia Commercial Trust
SGX:N2IU
|
SG |
|
PCCW Ltd
HKEX:8
|
HK |
|
V
|
Vincit Oyj
OMXH:VINCIT
|
FI |
|
888 Holdings PLC
LSE:888
|
GI |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Celularity Inc
NASDAQ:CELU
|
37.5m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Celularity Inc
Glance View
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company is headquartered in New York City, New York and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Celularity Inc is -119.6%, which is below its 3-year median of 8.3%.
Over the last 3 years, Celularity Inc’s Operating Margin has increased from -310.3% to -119.6%. During this period, it reached a low of -310.3% on Sep 30, 2022 and a high of 307.4% on Jun 30, 2023.
